How Khales was paid
$3.2M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Stock | Incentive | Other | Total |
|---|---|---|---|---|---|---|
| Payman KhalesPresident and CEO | $637,019 | — | $2,149,878 | $363,631 | $61,332 | $3,211,860 |
| Diron SmithExecutive Vice President and Chief Financial Officer | $499,135 | — | $1,724,858 | $321,007 | $23,964 | $2,568,964 |
| Lindsay K. BlackwoodSenior Vice President, General Counsel and Corporate Secretary | $365,385 | $50,000 | $1,024,856 | $203,656 | — | $1,643,897 |
| Andrew SennPresident, Cardio & Vascular | $434,135 | $250,000 | $799,959 | $195,190 | $28,640 | $1,707,924 |
| Jim StephensPresident, Cardiac Rhythm Management & Neuromodulation | $504,423 | — | $949,874 | $227,853 | $10,500 | $1,692,650 |
| Joseph W. DziedzicFormer President and CEO | $1,235,000 | — | $5,999,951 | $1,323,766 | $112,615 | $8,671,332 |
What changed and why
- $1.854BSales increased 8% year-over-year to $1.854 billion driven by new product ramps and recent acquisitions.
- $321MAdjusted operating income increased 13% to $321 million compared to the prior fiscal year.
- 21%Adjusted earnings per share increased 21% to $6.40 per share for the fiscal year.
- Payman Khales was appointed as President and Chief Executive Officer effective October 24, 2025.
- 98%Last year's say-on-pay proposal received support of approximately 98% of votes cast by stockholders.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.